Specifically, 20 oncogene alterations in BRAF, GNAQ, GNAS, KRAS, KIT, MET, NRAS, MAP2K1/MEK1, and PIK3CA were found in 44% of the LC cases as compared to eight alterations affecting 22% of LCNEC cases (Supplementary Table S3). The gene discussed is MAP2K1; the disease is large cell neuroendocrine carcinoma.